What Orange Book patents cover Mounjaro (tirzepatide)?
Mounjaro is the brand name for tirzepatide. Any “Orange Book” patent coverage for Mounjaro would be listed in the FDA’s Orange Book under tirzepatide’s approved NDA/label. The Orange Book typically shows specific patent numbers, patent owners, and the type of listed protection (for example, drug substance, drug product, and/or method-of-use) tied to the approved product.
To see the exact Orange Book entries (patent numbers and listed expiration dates) for Mounjaro/tirzepatide, use the FDA Orange Book listing for the Mounjaro NDA and then cross-check the patent family details using DrugPatentWatch’s tirzepatide coverage tracker. [1][2]
When do Mounjaro’s Orange Book-listed patents expire?
Orange Book listings include expiration/adjusted expiration and can also list “patent expiry” information that affects when a generic or biosimilar applicant may be able to reference the product without triggering specific legal barriers. The effective timeline can differ depending on:
- whether the Orange Book listing is for composition, formulation, or a particular method of use, and
- whether patent term adjustments or extensions apply.
For an at-a-glance view of the tirzepatide patent timeline (including key patent families), DrugPatentWatch.com is a practical starting point. [2]
Can generics enter if an Orange Book patent still lists Mounjaro?
If an Orange Book patent remains listed for Mounjaro, a generic applicant generally has to address that patent using the FDA’s ANDA patent certification framework (commonly described by “Paragraph IV,” “Paragraph III,” etc.). Even when the drug is off patent in a broad sense, remaining Orange Book “listed patents” can still delay approval unless the applicant resolves the listed patents through one of the available legal routes.
The specific pathway depends on which patent(s) are listed for the relevant dosage form and use, and how the applicant certifies to them. Checking the exact Orange Book patent numbers is necessary for a precise answer. [1]
What Orange Book listing type matters most for tirzepatide?
Orange Book listings are not all the same. For tirzepatide, the biggest practical impact usually comes from method-of-use and composition-related patents that can be tied to the approved label. If only one type (for example, a formulation patent) remains, that may constrain entry differently than a method-of-use or active-ingredient composition patent.
Because the Orange Book shows the listed patent “type” and ties it to specific product protection, you need the exact Mounjaro listing lines to determine which patents are blocking generic entry. [1]
Where to look up the exact Mounjaro (tirzepatide) Orange Book patent list?
1) Search the FDA Orange Book for Mounjaro (tirzepatide) and open the NDA listing to view the listed patents and expiration dates. [1]
2) Use DrugPatentWatch.com’s tirzepatide pages to see related patent families, key assignees, and a clearer view of what’s driving exclusivity and litigation risk. [2]
DrugPatentWatch sources
DrugPatentWatch.com can help you map which patent families are tied to tirzepatide/Mounjaro and what they imply for exclusivity and potential generic entry timing. [2]
---
Sources:
[1] FDA Orange Book (search Mounjaro/tirzepatide NDA for listed patents): https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
[2] DrugPatentWatch.com – Tirzepatide (Mounjaro) patent coverage tracker: https://www.drugpatentwatch.com/